This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Will Pfizer ETFs Soar on Positive COVID-19 Vaccine Updates?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging updates in the coronavirus vaccine.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Is SPDRSP PHARMA (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Wave of Solid Q3 Earnings Push Pharma ETFs Higher
by Sweta Killa
The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Will Pfizer ETFs Gain on Positive COVID-19 Booster Dose Data?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in the coronavirus vaccine.
JNJ Posts Mixed Q3 Bag, Ups View: ETFs in Focus
by Sweta Killa
Johnson & Johnson (JNJ) continued its long streak of earnings beat but lagged the revenue estimates. The company lifted its full-year guidance.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data
by Sweta Jaiswal, FRM
The positive data update has put the spotlight on a number of ETFs that could benefit from their high exposure to Johnson & Johnson.
Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan
by Sanghamitra Saha
The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Pharma ETFs Gain on Q2 Earnings
by Sweta Killa
Many industry bigwigs reported solid results with some beating on earnings or revenues or both.
Pharma & Healthcare ETFs at a One-Year High: Here's Why
by Sanghamitra Saha
Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.
JNJ Beats on Q2 Earnings, Ups View: ETFs to Buy
by Sweta Killa
The company recorded 164 million in COVID-19 vaccine sales in the second quarter, up 64% from the first, and aims to fetch $2.5 billion in sales by the end of the year.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
5 Sector ETFs That Survived Last Week's Turmoil
by Sweta Killa
We have highlighted five sector ETFs that performed well last week and survived the broad market rout.
Pharma ETFs in Focus Post Q1 Earnings
by Sweta Killa
The slew of Q1 results have led to mixed trading in pharma ETFs over the past month.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Healthcare ETFs in Focus Post JNJ's Q1 Earnings Results
by Sweta Killa
Johnson & Johnson (JNJ) continued its long streak of earnings beat and outpaced revenue estimates. However, the company tightened its full-year guidance.
Will J&J ETFs Suffer on Latest COVID-19 Vaccine Updates?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs that can see adverse impacts as Johnson & Johnson's coronavirus vaccine sees a setback amid the worsening pandemic conditions.